NHS to offer Wegovy to a million more people in England
The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Newsletters and Deep Dive digital magazine
The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.
Rocket Pharma has won FDA approval for the first gene therapy for LAD-I, a devastating genetic disorder causing severe vulnerability to infections.
Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.
Editor's Picks
Newsletters and Deep Dive
digital magazine